

SHELCAL 500

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory
abbreviated prescribing information for SHELCAL 500 (Calcium and Vitamin D3 Tablets)
[Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES: Vitamin D increases the intestinal absorption of calcium. Administration of calcium and vitamin D3 (cholecalciferol) counteracts the increase of parathyroid hormone (PTH), which is caused by calcium deficiency and which causes increased bone resorption.

INDICATION: SHELCAL is indicated 'for the prevention and treatment of Calcium and Vitamin D3 deficiency'

DOSAGE AND ADMINISTRATION: For oral use. Start with 1 tablet, twice daily with food or do as directed by physician. To be consumed with full glass of water or milk.

CONTRAINDICATION: Hypersensitivity to the active substances or to any of the excipients. Diseases and/or conditions resulting in hypercalcaemia and/or hypercalciuria (e.g. myeloma, bone metastases, primary hyperparathyroidism). Nephrolithiasis / nephrocalcinosis, severe renal impairment and renal failure, hypervitaminosis D, hypersensitivity to the active substances or to any of the excipients.

WARNINGS & PRECAUTIONS: Increased risk of hypercalcemia in case of patients with impaired renal function, sarcoidosis and immobilized patients with osteoporosis. Patients with kidney stones and renal impairment.

Milk-alkali syndrome (Burnett's syndrome), i.e. hypercalcaemia, alkalosis and renal impairment can develop when large amounts of calcium are ingested with absorbable alkali.

DRUG INTERACTIONS: Thiazide diuretics reduce the urinary excretion of calcium. Systemic corticosteroids reduce calcium absorption. Simultaneous treatment with ion exchange resins such as cholestyramine or laxatives such as paraffin oil may reduce the gastrointestinal absorption of vitamin D. Calcium salts may decrease the absorption of iron, zinc or strontium.

ADVERSE REACTIONS: Constipation, flatulence, nausea, abdominal pain, and diarrhoea

MARKETED BY:



TORRENT PHARMACEUTICALS LTD.
IN/SHELCAL 500/MAY 2022/02/ABPI

(Additional information is available on request)